1Department of Diagnostic Radiology, Kosin University Collegeof Medicine, Busan, Korea. 2Department of Neurosurgery, Dong-A University College ofMedicine, Busan, Korea. 3Department of Microbiology, Dong-A University College ofMedicine, Busan, Korea. 4Department of Diagnostic Radiology, Dong-A UniversityCollege of Medicine, Busan, Korea. 5Department of Pathology, Dong-A University College ofMedicine, Busan, Korea. gyhuh@daunet.donga.ac.kr
Published online: February 28, 2002.
ABSTRACT
PURPOSE: To obtain basic data for development of a glioblastoma-specific immunotoxin, the expression of variable cell surface receptors on a human glioblastoma xenograft model was evaluated, using NOD/SCID mice.
MATERIALS AND METHODS: We developed a xenograft model in NOD/SCID mice implanted with a human glioblastoma cell line (U-87MG). Immunohistochemical studies were performed on implanted tumor nodules (n=8) using antibodies against CD71, EGFR, IGF-IRalpha, CXCR4 and IL-4Ralpha.
RESULTS: Expression of IL-4Ralpha, in implanted tumornodules, was the highest of the cell surface receptors evaluated in this study. However, the endothelial cells in, and around, the tumor nodules also revealed immunopositivity against IL-4Ralpha. The immunoreactivity of IL-4Ralpha, and other surface receptors such as CD71, IGF-IRalpha and EGFR, was prominent in tumor nodules associated with tumor necrosis.
CONCLUSION: IL-4Ralpha would be a possible target for the development of glioblastoma-specific immunotoxin, although there are limitations due to its endothelial expression.
PDF Links
Full text via DOI
Download Citation 
